Oncology Xagena
Aggiornamento in Medicina
Antibodies that block programmed death 1 ( PD-1 ) receptor and its ligand, PD-L1, have shown durable responses in multiple cancer types. PD-1 has been shown to be upregulated in hepatitis C virus ( ...